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FLT-3 LIGAND ENHANCES THYMOPOIESIS IN HEMATOPOIETIC STEM
CELL TRANSPLANTS (HSCT) INVOLVING AGED DONOR AND RECIPIENT
MICE BY INCREASING SURVIVAL AND TRAFFICKING OF EARLY THYMO-
CYTE PROGENITORS
Williams, K.M., Moore, A.R., Gress, R.E. National Institutes of Health,
Bethesda, MD
Impaired thymopoiesis may contribute to graft-versus-host dis-
ease and poor clearance of infections. Early thymic precursor fre-
quency is a point of regulation for thymus reconstitution;
however, it is unknown if decreased thymus recovery with age is
due to the absence of thymus elements or marrow precursors.
To address this, we investigated whether marrow thymus precur-
sor frequency declines with age, contributes to poor aged thymus
recovery, and can be enhanced with FMS-like tyrosine kinase 3
(Flt-3), a growth factor for HSC. Total number of HSC (LSK,
Lineage- Sca-11 and cKit1) and Flt-3R1 LSK were equivalent
in the marrow of old (. 4 months) and young mice (1 month).
By ELISA, marrow concentration of Flt-3L was equivalent be-
tween old and young mice. Similarly, there was no difference in
splenic LSK numbers. However, the response to exogenous Flt-
3L was distinct by age. While young marrow was unaffected after
Flt-3L, in aged mice, total LSK and CCR91 thymus directed
LSK increased 4 fold (p\ 0.05). The proportion of LSK that ex-
pressed Flt-3R decreased in the marrow of older mice in response
to Flt3-L and LSK proliferation (Ki67 and BrdU) did not differ in
response to Flt3-L in old or young mice, consistent with im-
proved survival rather than proliferation. We then hypothesized
that Flt-3L treated cells may also traffic to peripheral spaces, sim-
ilar to GCSF. Consistent with this theory, in the spleen of old and
young mice, the Flt3-R1 LSK number increased in response to
Flt3-L (p \ 0.05). We then used aged Flt3-L knock-out mice
(Flt3-L2/2) to test whether survival and trafficking were part
of the mechanism of Flt3-L. Aged Flt3-L 2/2 mice had signifi-
cantly lower LSK and Flt3-R1 LSK in the marrow than wild
type aged counterparts, consistent with a deficient survival signal.
After Flt3-L exposure, although Flt3-R proportion was un-
changed in the marrow, LSK numbers increased significantly in
the spleen (p\ 0.05) with equivalent Ki67, suggesting LSK traf-
ficked from marrow to spleen. Aged donor Flt3-L treated marrow
with lupron-treated aged host increased donor thymocytes two-
fold within 5 weeks after transplantation (p \ 0.05) compared
to lupron alone. Collectively, these data suggest that marrow
LSK milieu contributes to thymus dysfunction in older donor/
host recipient pairs and that Flt-3L may improve thymus recovery
by enhancing survival and trafficking of older donor HSC.224
CD31CD41 AND CD31CD81-LYMPHOCYTES AS BIOMARKERS PRE-
DICTING THE LONG TERM OUTCOME OF PEDIATRIC HAEMATOPOIETIC
STEM CELL TRANSPLANTATION RECIPIENTS
Bartelink, I.H.1, Belitser, S.V.2, Knibbe, C.A.J.3,4, Danhof, M.4, de
Pagter, A.J.1, Egberts, A.C.G.1,2, Boelens, J.J.1 1UniversityMedical Cen-
ter Utrecht, Utrecht, Netherlands; 2Utrecht University, Utrecht, Nether-
lands; 3St. Antonius Hospital, Nieuwegein, Netherlands; 45 Leiden/
Amsterdam Center for Drug Research, Division of Pharmacology, Leiden
University, Leiden, Netherlands
Introduction: Haematopoietic stem cell transplantation (HSCT)
may be complicated by severe infectious complications, graft-ver-
sus-host disease (GvHD) and relapse/graft failures the probability
thereof depends on the lymphocyte immune reconstitution. The
goal of this study was to identify biomarkers of immune reconstitu-
tion in the first period after transplantation that may predict
outcome.Methods: Children transplanted between 2005-2007 in the
UMCU were prospectively included. Immunophenotyping was
performed every two weeks after HSCT. Several parameters of
immune reconstitution in relation with survival, acute- and
chronic-GvHD were studied, using a multiplicative intensity
model in R: AUC, the time and maximum CD31CD41,
CD31CD81 T-cell and CD191B-cell numbers, the ratio be-
tween CD4/CD8 and the relationship between naive and memory
cells in the period 0-90,0-180 and 180-360 days. Data were strat-
ified to donor source. Relations were tested in linear, logaritmic
and parabolar functions. The differences between models were
compared using the P-values and diagnostics of the model. Based
on the resulting model, we defined a cut off value to describe op-
timal survival per biomarker.
Results: 56 recipients received bone marrow, 12 received a sibling
donor, while 26 patients received cord blood derived stem cells.
The median age at HSCT was 5.9 years (range 0.11 – 18.1).
The max nr of CD41 cells related to their age related reference
values in the first 6 months after HSCT positively predicted sur-
vival (HR 0.43, CI95% 0.29-0.63), with a cutoff point of 0.15. In
Cord blood transplants the CD4/8 ratio within the first half year
. 5 was a predictor for survival (HR 5 0.6 CI95% 0.40-0.91).
In BM/sibling transplants, the maximum number of CD8 cells
related to their age related reference values . 1 positively pre-
dicted survival within the first half year (HR 5 0.68, CI95%
0.46-1.01).
Conclusion: CD31CD41 and CD31CD81 divided by their age
related reference values, predicted outcome early after HSCT in
children and may be used in future studies and in clinical practice,
after further validation of these relationships.225
IMMUNE RECONSTITUTION IN HEMATOPOIETIC CELL TRANSPLANTA-
TION PATIENTS RECEIVING ATG AS PART OF CONDITIONING REGIME
Hoegh-Petersen, M., Dhadda, M., Liu, Y., Hagel, L., Podgorny, P.J.,
Ugarte-Torres, A., Storek, J. University of Calgary, Calgary, AB, Canada
Introduction: Successful immunological recovery in recipients of
hematopoietic cell transplantation (HCT) is important for trans-
plant success. Use of anti-thymocyte globulin (ATG) as part of
the pre-transplant conditioning has shown to decrease graft versus
host disease (GvHD). However the impact of ATG on immuno-
logical recovery has not been studied. Here we studied the factors
influencing immune cell recovery after ATG-conditioned HCT.
Patients and Methods: Immune subsets were quantified in 176 al-
logeneic HCT recipients receiving ATG during conditioning, at day
28, 56, 84, 180, 365 and 730 post transplantation. Following lym-
phocyte subsets were quantified: B cells, CD4 T cells and CD8 T
cells (incl. their naive and memory/effector [mem/eff] subsets), NK
cells (incl. regulatory and cytolytic subsets), monocytes and dendritic
cells (DC) (incl. plasmacytoid and myeloid subsets). Day 7 serum
levels of ATGwere quantified by flow cytometry. Significance of as-
sociations between immune cell subset counts and factors suspected
to influence themwere tested usingMann-Whitney rank sum test for
categorical factors and Spearman rank correlation test for continu-
ous variable/factors.
Results: Higher recipient age was associated with lower na€ıve
CD4 and CD8 T cell counts on days 180, 365 and 730. Graft con-
tent of specific subsets positively correlated with counts of the
same subset early posttransplant in the case of B cells (both naive
and memory), CD4 and CD8 T cells (both naive and mem/eff),
and myeloid DCs. Significant GvHD (grade 2-4 acute or moder-
ate-severe chronic) was associated with significantly lower B cell
counts (including naive and memory) on days 56-180, regulatory
NK cells on days 28-56, plasmacytoid DCs on day 28-84 and
higher counts of naive CD8 T cells on days 28-84. High day 7 se-
rum ATG levels were associated with decreased CD4 and CD8 T
cell counts and increased regulatory NK cell counts early, but for
most subsets not late posttransplant. Graft CD34 cell count and
recipient CMV serostatus showed no positive correlation with
any immune cell subset count.
Poster Session I S237Conclusion: Counts of T cells, B cells and myeloid DCs early
posttransplant depend on the number of these cells infused with
the graft. Naive T cell counts late posttransplant depend on
recipient age. GVHD appears to hamper the recovery of B cells,
regulatory NK cells and plasmacytoid DCs. Day 7 ATG serum
levels have a significant impact on T cell counts in the first 3
months posttransplant.226
KGF PROMOTES CD41 T CELL RECOVERY AFTER T-CELL DEPLETED
ALLOGENEIC HEMATOPOEITIC STEM CELL TRANSPLANTATION IN
PATIENTS CONDITIONED WITH TOTAL BODY IRRADIATION: IMPACT
ON OVERALL SURVIVAL
Goldberg, J.D.1, Zheng, J.2, Small, T.N.3, Castro-Malaspina, H.1,
Jakubowski, A.A.1, Heller, G.2, van den Brink, M.R.M.1, Perales, M.-A.1
1Memorial Sloan-Kettering Cancer Center, New York, NY; 2Memorial
Sloan-Kettering Cancer Center, New York, NY; 3Memorial
Sloan-Kettering Cancer Center, New York, NY
Delayed immune recovery (IR) after allogeneic HSCT (allo-
HSCT) is associated with increased risks of infection and relapse,
which can impact survival. Studies by others and us have shown in
pre-clinical mouse models that pre-HSCT administration of KGF
resulted in increased thymopoiesis and peripheral T-cell numbers
post allo-HSCT. Therefore, we performed a retrospective study to
evaluate the effect of KGF (Palifermin, Biovitrium) on IR in allo-
HSCT recipients. We conducted a review of 241 consecutive
patients who underwent an ablative T-cell depleted allo-HSCT
from 2005-2009. The conditioning regimen was TBI-based in 114
patients and chemotherapy-based in 127 patients. 160 patients
(66.4 %) received KGF peri-transplant. IR data (CD4, CD8, NK,
CD45RA, PHA response) were collected for one year after HSCT
and censored following DLI (n5 49), 2nd transplant (n5 21) or In-
terleukin 7 treatment (n5 8). A joint longitudinal survival model was
used to characterize the profile of IR data over time (longitudinal
model) and the association between immunologic data and survival
(survival model; overall survival (OS) and event-free survival
(EFS)). In the joint OSmodel analysis of TBI recipients, administra-
tion of KGF was marginally significantly associated with recovery of
CD4 count (slope 5 0.29, p 5 0.059) and there was a trend for an
association between CD4 recovery and OS (HR 5 0.69, p 5
0.077). With a similar association between administration of KGF
and recovery of CD4 count, CD4 recovery was not found to be asso-
ciated with EFS. For patients who received chemotherapy-based
preparative regimens, KGF had no impact on CD4 recovery.
However, in these patients, CD4 recovery was associated with an in-
creasedOS (HR5 0.61, p5 0.006) andEFS (HR5 0.56, p5 0.023).Table 1. Joint Longitudinal Survival Model
Regimen
Survival
Parameter
Longitudinal Model,
effect of KGF – CD4
Survival
Model – CD4
Slope (of log
transformed
CD4 count) 95% CI P-value HR 95% CI P-value
TBI OS 0.29 -0.010.59 0.059 0.69 0.461.04 0.077
TBI EFS 0.29 -0.020.60 0.063 0.69 0.411.17 0.171
Chemo OS NS NS NS 0.61 0.430.87 0.006
Chemo EFS NS NS NS 0.56 0.340.92 0.023For the combined group of patients, CD4 recovery was associated
with improvedOS (HR 0.65, p0.002), but not EFS; KGF did not im-
pact CD4 recovery. Administration of KGF did not impact the re-
covery of other immune subsets. This analysis is potentially
limited by its retrospective nature and the length of the study time
frame. However, our data suggest that KGF improves CD4 recovery
in recipients of TBI-based conditioning regimens, which in turn is
associated with increased OS. This data is consistent with the pre-
clinical data and clinical mucositis data suggesting the effect of
KGF may depend on the preparative regimen. A prospective trial
is warranted to further investigate these promising findings.227
RECOVERY OF FUNCTIONAL T CELLS SPECIFIC FOR PERSISTING VIRUS IS
NOT IMPAIRED IN PATIENTS WITH CHRONIC GRAFT-VS-HOST DISEASE
Hoegh-Petersen,M.1, Liu, Y.1, Liu, S.1, Ugarte-Torres, A.1, Fonseca, K.2,
Khan, F.1, Storek, J.1 1University of Calgary, Calgary, AB, Canada;
2Alberta Health Services, Calgary, AB, Canada
Introduction: T cell expression of PD-1, a marker of functional ex-
haustion manifested by inability to produce cytokines upon stimula-
tion, is upregulated in patients with acute graft-vs-host disease
(GHVD). This is thought to explain at least in part why patients
with acute GVHD have frequent infections. Here we wished to eval-
uate whether this is true also for chronic GVHD.
Patients and Methods: We studied 17 allogeneic hematopoietic
cell transplant recipients who have not developed acute or chronic
GVHD by day 84. Between day 84 and 365, 7 patients did and 10
patients did not develop chronic GVHD needing systemic immuno-
suppressive therapy (de novo, ie, without preceding acute GVHD).
We studied total CD4 and CD8 T cells as well as Epstein-Barr virus
(EBV)-specific CD4 andCD8T cells. Bloodmononuclear cells were
stimulated with EBV lysate or EBNA3A1B1C overlapping pep-
tides. After overnight incubation, expression of IFNg, TNFa, IL2
and PD-1 on CD31CD41CD8- or CD31CD4-CD81 cells was
determined by flow cytometry.
Results: PD-1 expression on total, EBV lysate-specific or EBNA3-
specific CD4 or CD8 T cells was not significantly higher among pa-
tients who did vs did not develop chronic GVHD. On the contrary,
there was a trend toward lower PD-1 expression on EBV lysate-spe-
cific CD4 and CD8 T cells and EBNA3-specific CD4 T cells in pa-
tients who developed chronic GVHD. This was significant (p\ .05,
Mann-Whitney test) for EBV lysate-specific CD4 T cells on day 84,
EBV lysate-specific CD8 T cells on day 180, EBV lysate-specific
CD4 and CD8 T cells on day 365, EBNA3-specific CD4 T cells on
day 84 and EBNA3-specific CD4 T cells on day 365. Consistent
with that, absolute counts of total, EBV lysate-specific or EBNA3-
specific T cells were not significantly lower in patients who did vs
did not develop chronic GVHD. On the contrary, there was a trend
toward higher EBV lysate-specific and EBNA3-specific CD4 or
CD8 T cell counts in patients who developed chronic GVHD. This
was significant on day 84 for total EBV lysate-specific CD4 and
CD8 cells, EBV lysate-specific CD41IFNg1 cells and CD81IFNg1
cells, and total EBNA3-specific CD4 cells, EBNA3-specific
CD41IFNg1 cells, CD41IL21 cells, CD41IFNg1TNFa1IL21
cells and CD81IFNg1 cells.
Conclusion: De novo chronic GvHD and its treatment do not ad-
versely affect the counts of functional T cells specific for EBV and,
perhaps, for persisting viruses in general.
